BridgeBio Pharma, Inc.

NASDAQ:BBIO

Biotechnology

Healthcare
$78.01 +1.13%

+$0.75 today

Market cap
$15.20B
Beta
0.97
P/E (TTM)
-18.1
EPS (TTM)
-$3.73
52W Low $40.19High $84.94

Volume 3.55M

Average 2.49M

BBIO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

BridgeBio Pharma, Inc.NASDAQ: BBIO

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $1.05M fell 20.0% year over year, behind the -7.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 11.2% from the prior quarter. Over 3 fiscal years it compounded at -7.1% a year.

Context

  • Depreciation & amortization amounted to 1.1% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -20.0% toward the trailing-twelve-month pace of -7.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.05M-11.2% QoQ
Last fiscal yearDec 2025
$5.43M-10.6% YoY
LTMJun 2026
$5.07M-7.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.0%——
1 year-10.6%——
3-year CAGR-7.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
5.43M USD
Year-over-year change
-10.6%
4-year CAGR
-1.8%

Depreciation & Amortization vs competitors

How BBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.9% is the 8th highest of 11, against a peer median of +1.3%.
  • Depreciation & amortization amounts to 0.7% of revenue for BBIO, versus a peer median of 5.3%.
BBIO Competitors
Depreciation & Amortization for BBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$134.49M USD+62.6%-7.9%0.0%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$55.3M USD+97.1%-33.0%5.5%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$54.76M USD-3.1%+7.8%1.1%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$47.58M USD-13.0%+43.1%7.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$34.01M USD-4.7%+24.3%5.1%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$21.89M USD+6.2%+0.9%2.3%
ASNDAscendis Pharma A/SLTM Sep 2026€18.33M EUR+5.7%-1.8%1.5%
DNLIDenali Therapeutics Inc.LTM Jun 2026$13.14M USD+17.5%+12.6%364.7%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$5.07M USD-7.9%-7.1%0.7%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$2.16M USD-28.6%-14.3%10.8%
SRRKScholar Rock Holding CorporationLTM Sep 2026$1.32M USD-19.2%-17.8%230.7%
Peer median (excluding BBIO) —+1.3%-0.5%5.3%

Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue69.72M77.65M9.3M221.9M502.08M
Cost of Revenue3.11M3.43M2.45M3.88M28.27M
Gross Profit66.6M74.21M6.86M218.02M473.81M
Gross Margin95.5%95.6%73.7%98.3%94.4%
Research & Development451.02M399.46M455.71M506.46M477.54M
Selling, General & Admin192.21M143.19M150.59M288.93M555.14M
Operating Expenses643.23M586.42M614.23M811M1.04B
Depreciation & Amortization5.84M6.77M6.49M6.08M5.43M
EBITDA(533.83M)(397.44M)(565.47M)(436.83M)(676.45M)
EBITDA Margin-765.7%-511.9%-6078.3%-196.9%-134.7%
Operating Income(576.63M)(512.2M)(607.37M)(592.97M)(569.09M)
Operating Margin-827.1%-659.6%-6528.8%-267.2%-113.3%
Interest Income1.13M7.54M18.04M17.25M19.85M
Interest Expense46.78M80.44M81.29M99.29M53.1M
Other Income / Expenses(9.82M)27.55M(45.88M)50.78M(165.9M)
Income Before Tax(586.45M)(484.65M)(653.25M)(542.19M)(734.99M)
Pre-Tax Margin-841.2%-624.2%-7021.9%-244.3%-146.4%
Income Tax Expense0001.15M555K
Net Income(562.54M)(481.18M)(643.2M)(535.76M)(729.31M)
Net Margin-806.9%-619.7%-6913.9%-241.4%-145.3%
EPS (Basic)(3.90)(3.35)(3.95)(2.88)(3.79)
EPS (Diluted)(3.90)(3.35)(3.95)(2.88)(3.79)
Weighted Avg Shares144.36M147.47M162.79M186.08M197.24M
Weighted Avg Shares (Diluted)144.36M147.47M162.79M186.08M197.24M

BridgeBio Pharma, Inc.

NASDAQ:BBIO

Intrinsic Alpha fair value

Locked

Current Price

$78.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.